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ABSTRACT
Introduction: As both anti-tumour effects and toxicity are thought to be dose-dependent, patients
with the greatest toxicity may also have the best outcome. We assessed whether severity of doxorubi-
cin-induced hematological toxicity is associated with outcome in advanced soft tissue sarcoma (STS)
patients. In addition, risk factors for hematological toxicity were explored.
Methods: Worst haematological toxicities (anaemia, leukopenia, neutropenia and thrombocytopenia)
seen during treatment were scored according to CTCAE toxicity score. Differences in overall survival
(OS), progression free survival (PFS) and response rate (RR) between patients with or without high
haematological toxicity (grades 0–2 vs. 3–4) were assessed using conventional statistical tests.
Associations between baseline characteristics and hematological toxicity were established using logistic
multivariate regression.
Results: In 557 patients eligible for this analysis, 47.2% of the patients received at least six cycles of
treatment; 45% stopped treatment early due to progression, 3% because of toxicity. Relative dose
intensity (RDI) was constant over the cycles.
OS, PFS, and RR did not differ between patients with grade 3/4 toxicity during treatment versus those
with grade 1/2. Risk factors for grade 3/4 haematological toxicity, in particular neutropenia, were age
above 60 years, low BMI, and female gender.
Conclusion: In this large series, risk factors for haematological toxicity in STS patients receiving doxorubi-
cin monotherapy were revealed. The finding that there was no association between outcome and haem-
atological toxicity during doxorubicin treatment may be useful to reassure advanced STS patients that
failure to experience haematological toxicity during treatment does not equate to under-treatment.
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Introduction
Soft tissue sarcomas (STS) are a rare group of tumours con-
sisting of numerous different subtypes displaying great vari-
ation in molecular characteristics, clinical behaviour, and
sensitivity to anti-tumour agents. Patients with advanced dis-
ease not amenable to local treatment options with curative
intent have a dismal prognosis, with a median overall sur-
vival of approximately 1 year. For these patients, palliative
treatment is indicated.
In the first line setting, numerous drugs have been shown
to exert anti-tumour activity. Of these, doxorubin and ifosfa-
mide are the most commonly used agents. Given equivalent
efficacy of doxorubicin and ifosfamide [1], doxorubicin is pre-
ferred, given more convenience for the patients as doxorubi-
cin can be administered once every three weeks in an
outpatient setting. Recently, a randomised EORTC study com-
pared doxorubicin monotherapy versus the combination of
doxorubicin and ifosfamide [2]. Although response rate and
progression-free survival were greater in the patients treated
with the combination, overall survival, the primary endpoint
in this study, was not statistically different. Consequently,
apart from patients whose primary need is tumour shrinkage,
have a good clinical condition and adequate organ function
and for whom the combination may be preferred, doxorubi-
cin monotherapy is still considered standard for the majority
of advanced STS patients [3]. Recently, it was shown in a
randomized phase II study that the addition of the anti-plate-
let-derived growth factor receptor-alpha (PDGFRA) monoclo-
nal antibody, olaratumab, to doxorubicin improved overall
survival compared with doxorubicin alone [4] resulting in
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approval of this drug in combination with doxorubicin.
But given the preliminary nature of these results, in many
centres, doxorubicin will remain the mainstay of treatment
for many advanced STS patients.
The most commonly used schedule of doxorubicin mono-
therapy in advanced STS patients is 75mg/m2 every three
weeks for a maximum of six cycles. As holds true for all anti-
tumour agents, the pharmacokinetics of doxorubicin and its
metabolites greatly differs between patients. This large var-
iety in doxorubicin PK between patients may partially
account for the great variation in toxicities experienced by
patients [5]. Accordingly, a statistically significant association
was revealed between systemic doxorubicin blood levels and
myelosuppression in a small series of patients with small cell
lung cancer [6].
Given this relationship between systemic exposure to
doxorubicin and haematological toxicity on one hand and a
suggested dose-response association for doxorubicin in
advanced STS [7] on the other hand, a relationship between
doxorubicin-induced toxicity and outcome may exist in
advanced STS. It is important to know whether such a rela-
tionship indeed exists in advanced STS for a number of rea-
sons. In daily practice, many patients who do not experience
any significant toxicity from doxorubicin are worried about
whether or not the treatment ‘works’, in other words
whether the chemotherapy actually exerts anti-tumour
effects. Furthermore, if such a relationship does exist, the
occurrence and severity of toxicity might be an early marker
for response and in principle, could serve to guide treatment,
i.e., increasing the dose up to toxicity.
In this study, we retrospectively examined the relationship
between the severity of haematological toxicities and efficacy
in a large series of advanced STS patients treated with first-
line doxorubicin monotherapy. In addition, risk factors for
haematological grade 3/4 toxicity were explored.
Patient and methods
Patients
In the EORTC database, nine studies were identified in which
advanced STS patients were treated with doxorubicin mono-
therapy 75mg/m2 every three weeks. No G-CSF, erythropoi-
etin or dexrazoxane was allowed in any of the studies. In
case of toxicity, dose reduction had to be applied. This ana-
lysis was focused only on patients who received at least one
cycle of treatment and with at least one post-baseline labora-
tory assessment leaving a total of seven eligible EORTC trials
conducted between 1990 and 2012 with a total of 557
patients eligible for this analysis (Supplementary Table 1).
Endpoints
The endpoints for outcome considered for this analysis were
overall survival (OS), progression-free survival (PFS) and
response rate (RR). OS was defined as the time elapsing
between the date of randomization (in the randomized trials)
or registration (in the non-randomized trials) and the date of
death. Patients alive at the last follow-up date were censored.
PFS was defined as the time between date of randomization
(in the randomized trials) or registration (in the non-random-
ized trials) and the date of first progression or death, which-
ever came first. Patients who are alive without progression at
the last follow-up date are censored. RR was evaluated in all
trials using WHO response criteria or RECIST in which patients
who achieved a complete or partial response were consid-
ered as ‘responders’, and patients with stable disease or in
progression are considered as ‘non-responders’. Best
responses were used.
Risk factors
This analysis was focused on four hematological toxicities:
anaemia, leukopenia, neutropenia and thrombocytopenia. For
each of the four toxicities, the Common Terminology Criteria
for Adverse Events version 4.0 (CTCAE v4.0) scoring from
grade 0 to grade 4 was used. Patients experiencing grade
0–2 toxicity as the highest toxicity during treatment were
considered as patients with ‘low toxicity’, those patients with
grade 3–4 toxicity as most severe toxicity during treatment
as patients with ‘high toxicity’.
In all but two studies, a full blood count was done weekly.
In the two other studies (EORTC 62901 (N¼ 112) and EORTC
62091 (N¼ 43), a full blood count was mandated during the
first two cycles and then prior to each subsequent adminis-
tration of doxorubicin. However, additional analyses (results
not shown) showed that many investigators obtained weekly
blood counts in these studies as well and that the number of
obtained blood samples from these studies did not differ too
much from the other studies where weekly blood counts
were mandated.
If the laboratory values were measured more than once
per cycle, then the worst (minimum) value was considered.
When a specific laboratory value was not reported (missing
value) but other laboratory data were reported at the same
time, it was assumed that the specific toxicity was in the nor-
mal range and toxicity grade zero was imputed for that spe-
cific toxicity grade.
Several potential confounders for the association of doxo-
rubicin-induced toxicity and outcome were extracted from
the database. The relative dose intensity (RDI) was calculated
as the ratio of actual doxorubicin dose intensity (adminis-
tered dose/actual duration of cycle in days) to the intended
doxorubicin dose intensity (planned dose/standard cycle dur-
ation of 21 days) per cycle. For the calculation of adminis-
tered dose, BSA was calculated using the weight value
reported per patient by cycle and height value reported at
baseline. When weight was missing, the last weight available
was used for the calculation of RDI.
Other characteristics assessed were demographic factors
(age, gender and WHO performance status), and tumour
characteristics (STS histological subtype, histopathological
grading (low (grade I) versus high grade (grade II and III),
time between initial diagnosis and start of chemotherapy,
primary site, metastatic sites, and the presence of local recur-
rence and metastatic disease).
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Statistical analyses
Hematologic toxicity values and grades were summarised by
cycle. The time between treatment start and occurrence of
first toxicity grade was depicted using a Cumulative
Incidence graph to investigate, at which time, higher grades
of toxicity occurred.
To compare the PFS and OS between patients with low
(grade 0–2) versus those with high haematological toxicities
(grade 3–4), Kaplan–Meier methods and the log-rank test
were used. To avoid potential bias from patients who
received only one, two or three cycles of treatment, landmark
analyses were performed to compare the results at the end
of cycle 1, cycle 2 and cycle 3. Patients who progressed, died
or discontinued before the different landmark analyses were
excluded from these analyses.
To explore whether RR differed between patients with or
without high hematologic toxicities (0–2 vs. 3–4), the Chi-
square test was used for the subgroups of patients still on
treatment at the end of cycle 1, cycle 2 and cycle 3. Patients
who stopped treatment before each time point were
excluded from these analyses.
Associations between baseline characteristics (gender,
body mass index, performance score, and age) and hemato-
logical grade 3/4 toxicity were established using logistic
multivariate regression modeling.
Results
Patients’ characteristics
A total number of 557 sarcoma patients from 7 EORTC trials
(conducted between 1990 and 2012) were considered for
this analysis. The analysis was based on patients who
received at least one cycle of treatment, for a total number
of cycles of 2341.
The patients’ characteristics per protocol are depicted in
Table 1. The majority of patients (32%) were between 50 and
Table 1. Patient characteristics.
Patient’s characteristics by protocol
Protocol
62901
(N¼ 101)
62941
(N¼ 38)
62962
(N¼ 41)
62971
(N¼ 99)
62012
(N¼ 203)
62061
(N¼ 37)
62091
(N¼ 38)
Total
(N¼ 557)
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Gender
Male 49 (48.5) 22 (57.9) 18 (43.9) 51 (51.5) 95 (46.8) 21 (56.8) 16 (42.1) 272 (48.8)
Female 52 (51.5) 16 (42.1) 23 (56.1) 48 (48.5) 108 (53.2) 16 (43.2) 22 (57.9) 285 (51.2)
Age
<40 yrs 14 (13.9) 10 (26.3) 5 (12.2) 21 (21.2) 48 (23.6) 0 (0.0) 2 (5.3) 100 (18.0)
40–50 yrs 28 (27.7) 7 (18.4) 14 (34.1) 26 (26.3) 74 (36.5) 0 (0.0) 4 (10.5) 153 (27.5)
50–60 yrs 32 (31.7) 11 (28.9) 11 (26.8) 32 (32.3) 74 (36.5) 9 (24.3) 11 (28.9) 180 (32.3)
>¼60 yrs 27 (26.7) 10 (26.3) 11 (26.8) 20 (20.2) 7 (3.4) 28 (75.7) 21 (55.3) 124 (22.3)
Performance status
PS 0 32 (31.7) 11 (28.9) 10 (24.4) 46 (46.5) 115 (56.7) 20 (54.1) 25 (65.8) 259 (46.5)
PS 1 57 (56.4) 24 (63.2) 26 (63.4) 53 (53.5) 88 (43.3) 17 (45.9) 13 (34.2) 278 (49.9)
PS 2þ 12 (11.9) 3 (7.9) 5 (12.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 20 (3.6)
Histopathological aggressivity
Low 16 (15.8) 9 (23.7) 4 (9.8) 8 (8.1) 13 (6.4) 5 (13.5) 0 (0.0) 55 (9.9)
High 60 (59.4) 14 (36.8) 14 (34.1) 91 (91.9) 190 (93.6) 32 (86.5) 4 (10.5) 405 (72.7)
Missing 25 (24.8) 15 (39.5) 23 (56.1) 0 (0.0) 0 (0.0) 0 (0.0) 34 (89.5) 97 (17.4)
Site of primary tumor
Other 27 (26.7) 18 (47.4) 29 (70.7) 56 (56.6) 113 (55.7) 26 (70.3) 27 (71.1) 296 (53.1)
Extremities 11 (10.9) 17 (44.7) 12 (29.3) 41 (41.4) 89 (43.8) 10 (27.0) 9 (23.7) 189 (33.9)
Missing 63 (62.4) 3 (7.9) 0 (0.0) 2 (2.0) 1 (0.5) 1 (2.7) 2 (5.3) 72 (12.9)
Histology
Leiomyosarcoma 43 (42.6) 11 (28.9) 9 (22.0) 21 (21.2) 42 (20.7) 15 (40.5) 12 (31.6) 153 (27.5)
Synovial sarcoma 7 (6.9) 4 (10.5) 4 (9.8) 10 (10.1) 34 (16.7) 1 (2.7) 4 (10.5) 64 (11.5)
Liposarcoma 14 (13.9) 6 (15.8) 7 (17.1) 15 (15.2) 23 (11.3) 8 (21.6) 12 (31.6) 85 (15.3)
Other 34 (34.0) 17 (24.5) 21 (28.3) 52 (54.7) 84 (41.7) 13 (38.8) 10 (30.9) 231 (41.5)
Missing 3 (3.0) 0 (0.0) 0 (0.0) 1 (1.0) 20 (9.9) 0 (0.0) 0 (0.0) 24 (4.3)
Prior Surgery
No surgery 0 (0.0) 4 (10.5) 4 (9.8) 22 (22.2) 203 (100.0) 37 (100.0) 38 (100.0) 105 (18.9)
Non optimal surgery 0 (0.0) 5 (13.2) 11 (26.8) 13 (13.1) 0 (0.0) 0 (0.0) 0 (0.0) 29 (5.2)
Complete surgery 0 (0.0) 22 (57.9) 20 (48.8) 55 (55.6) 0 (0.0) 0 (0.0) 0 (0.0) 97 (17.4)
Missing 101 (100.0) 7 (18.4) 6 (14.6) 9 (9.1) 0 (0.0) 0 (0.0) 0 (0.0) 326 (58.5)
Prior radiotherapy
No 77 (76.2) 19 (50.0) 29 (70.7) 75 (75.8) 130 (64.0) 37 (100.0) 38 (100.0) 405 (72.7)
Yes 24 (23.8) 19 (50.0) 12 (29.3) 23 (23.2) 73 (36.0) 0 (0.0) 0 (0.0) 151 (27.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2)
Primary site involved
No 0 (0.0) 25 (65.8) 19 (46.3) 46 (46.5) 110 (54.2) 15 (40.5) 21 (55.3) 236 (42.4)
Yes 0 (0.0) 13 (34.2) 22 (53.7) 53 (53.5) 93 (45.8) 17 (45.9) 17 (44.7) 215 (38.6)
Missing 101 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (13.5) 0 (0.0) 106 (19.0)
Metastatic Site involved
No 0 (0.0) 3 (7.9) 4 (9.8) 13 (13.1) 0 (0.0) 7 (18.9) 5 (13.2) 32 (5.7)
Yes 0 (0.0) 35 (92.1) 37 (90.2) 86 (86.9) 189 (93.1) 30 (81.1) 33 (86.8) 410 (73.6)
Missing 101 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 14 (6.9) 0 (0.0) 0 (0.0) 115 (20.6)
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60 years old at registration, 51% were female. Almost all
patients had a PS of 0 or 1 and 72% had a grade II or III
tumor. Leiomyosarcoma (28%) and liposarcoma (15%) were
the most frequent STS subtypes entered in these studies.
Treatment exposure
Two hundred sixty three out of 557 (47.2%) patients received
at least six cycles of treatment: 220 (39.5%) patients stopped
treatment after 6 cycles and 43 (7.8%) received more than 6
cycles. The latter group concerned patients from the two old-
est trials (62901 and 62941) in which a maximum of 8 and 7
cycles, respectively, were allowed per protocol whereas in
the more recent trials, the maximum number of cycles was
set at 6.
The median time on treatment, defined as the time in
weeks between the start date of treatment and the end date
of the last cycle reported (i.e., the date of administration of
the last cycle of doxorubicin þ21 days), was 15 weeks
(Figure 1) corresponding with a median time on treatment of
around five cycles. After 9 weeks of treatment (3 cycles),
63.7% of the patients were still on treatment.
Patients interrupted treatment mainly due to progressive
disease (45%), only 19 patients (3%) stopped because of tox-
icities. Forty percent of patients completed the maximum
number of cycles per protocol. The relative dose intensity
was constant over cycles and was concentrated around 100%
(Figure 2).
Hematologic toxicity
The distribution of the hematologic laboratory values over
the first 6 cycles of chemotherapy is depicted in Figure 3.
The worst toxicity grade per cycle is displayed in Figure 4. At
baseline, 90% of the patients had grade 0 or 1 toxicity. The
percentage of patients having grade 2 toxicity increased over
time from 17% at cycle 1 to 24% at cycle 3. After cycle 1, the
percentage of patients experiencing grade 3 toxicity was
quite constant over cycle, while the percentage of patients
with grade 4 tended to decrease after cycle 1, from 21.0% at
cycle 2 to 12% at cycle 3. This tendency was not related to
the interruption of the treatment since the majority of
patients with grade 3/4 toxicity during cycle 1 did not gener-
ally interrupt the treatment after cycle 1. Out of 106 patients
with grade 3 and 118 patients with grade 4 at cycle 1,
respectively, 93 and 90% continued treatment after cycle 1
and 53 and 42%, respectively, were still on treatment at cycle
6, which is comparable with patients with grade 0–2 toxicity
during cycle 1.
Response to treatment and association with toxicity
Ninety one (16.3%) patients had a CR or PR as best response,
453 (81.3%) patients had progression or stable disease. In
patients with grade 0–2 toxicity as worst toxicity, the RR was
11.8% (28/238 patients), in patients with grade 3/4 toxicity,
the RR was 19.7% (63/319 patients). Since this comparison
could be biased by the fact that worst toxicity may have
occurred after the best response on treatment, the relation-
ship of response with the worst toxicity was separately done
at cycle 1, 2 or 3, considering only patients still on treatment
at that cycle. For patients with grade 0–2 toxicity versus
those with grade 3/4 toxicity, the respective RRs were 14.9%
versus 19.0% at cycle 1 (p¼ .44), 15.1% versus 20.2% at cycle
2 (p¼ .264), and 21.0 versus 25.2% at cycle 3 (p¼ .435).
Figure 1. Time on treatment.
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Figure 2. Relative dose intensity (RDI). RDI (i.e., the actual dose intensity compared to the theoretical one, in %). RDI1 is relative dose intensity during cycle 1, RDI2
during cycle 2, RDI3 during cycle 3.
Figure 3. Worst hematological toxicity per cycle. X-axis: ‘0’ refers to values observed at baseline.
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Progression free survival and association with toxicity
Five hundred thirty nine (96.8%) patients progressed or died
during follow-up; 18 (3.2%) patients were still alive without
progression at the last available follow up. To investigate the
influence of severity of toxicity on PFS, a landmark analysis
was performed. Kaplan–Maier plots to compare the results at
the end of cycle 1, 2 and 3 were made in which patients
who died, progressed or discontinued treatment before each
of those cut-offs were not considered in the analysis.
The median PFS (95% Confidence Interval (CI)) of patients
with low hematologic toxicity (grade 0–2) versus those with
severe hematological toxicity (grade 3–4) during cycle 1 was
17.7 (12.7–21.1) weeks versus 21.0 (15.0–24.3) weeks (HR 0.85
(0.71–1.01); p¼ .066), during cycle 1–2, 21.2 (19.1–24.6) weeks
versus 15.8 (11.4–20.8) weeks (HR 0.91 (0.75–1.10); p¼ .316),
and during cycle 1-3, 27.9 (24.1–32.7) weeks versus 30.9
(27.4–32.9) weeks (HR 0.93 (0.75–1.16); p¼ .518).
Also for each specific hematologic toxicity (anemia,
thrombocytopenia, leukocytopenia, and neutropenia) land-
mark analyses were conducted at the end of cycle 1, 2 and
3. Given the low number of patients experiencing thrombo-
cytopenia grade 3/4, the analysis for thrombocytopenia was
not possible. For none of the assessments done, was there a
statistically significant difference in PFS between patients
with low grades of toxicity versus those with high grades of
toxicity. To illustrate, the PFS curves for the subgroups of
patients with low versus high toxicity occurring during cycle
1–3 are depicted in Figure 5.
Overall survival and association with toxicity
With respect to OS, 437 (78.5%) patients died during follow-
up, while 120 (21.5%) patients were still alive at the last avail-
able follow up. For the association of hematologic toxicity
and OS landmark analyses were also conducted using the
same cut-offs as were used in the PFS analyses.
The median OS (95% CI) of patients with low hematologic
toxicity (grade 0–2) versus those with severe toxicity (grade
3–4) during cycle 1 was 52.1 (45.1–61.6) weeks versus 54.1
(46.3–63.6) weeks (HR 0.97 (0.80–1.17) p¼ .739), during cycle
1–2, 59.6 (49.7–67.0) weeks versus 55.2 (49.1–65.9) weeks (HR
0.99 (0.81, 1.21); p¼ .924), and during cycle 1–3, 67.0
(57.3–78.7) weeks versus 64.0 (54.1–72.1) weeks (HR 1.04
(0.82, 1.32)); p¼ .729) (Figure 6).
Also for OS, analyses were done for each of the hemato-
logic toxicities separately with the exception of thrombocyto-
penia, given the low number of patients with greater than
grade 3 thromobocytopenia. As for PFS, there were no statis-
tically significant associations between the occurrence of any
of the hematologic toxicities assessed and OS. Results are
shown for the subset of patients with time on treatment and
OS 63 days (N¼ 383).
Baseline characteristics and grade 3/4
hematological toxicity
The association between the baseline characteristics (age,
gender, BMI and performance score) and grade 3/4 hemato-
logical toxicity is displayed in Table 2. Female gender, higher
age and a low BMI appeared to be associated with grade 3/4
hematological toxicity, in particular grade 3/4 neutropenia.
Discussion
In this large series of advanced STS patients treated with
doxorubicin monotherapy, we have identified several predic-
tors for doxorubicin-induced hematological toxicity, but
could not demonstrate an association of treatment-induced
toxicity with outcome.
After administration, doxorubicin is partially converted
into several metabolites with doxorubicinol being the major
metabolite [6,8,9]. Like almost all anti-tumour agents, the
pharmacokinetics of doxorubicin and its metabolites vary
widely between patients with inter-individual coefficients of
variation for area under the curve, volume of distribution,
and clearance being in the range of 60–90% [6,8]. Several
mechanisms may underlie this inter-individual variation
including differences in hepatic function [6], gender, BMI [5]
Figure 4. Worst overall toxicity grade per cycle.
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and genetic variants in genes encoding products involved in
the metabolism of doxorubicin [10].
Several previous studies have underlined the importance
of pharmacokinetics for doxorubicin-induced adverse events.
For example, doxorubicin-induced cardiotoxicity has been
suggested to be maximum-concentration dependent, and
should in that respect be given as an infusion rather than as
a bolus, while leucopenia is more related to the AUC [10]. In
a study in patients with small cell lung cancer, there
appeared to be a strong correlation between the AUC of
doxorubicin and leucocytes, while no relationships were
found for hematologic toxicity with levels of doxorubicin’s
main metabolite, doxorubinicol [6]. In the study, population
described here in which 93% of patients had a good WHO
performance score (0–1), doxorubicin was generally very well
tolerated. The RDI in those patients who did not have to ter-
minate treatment because of progressive disease, remained
constant at 100% over treatment and only 3% of the patients
had to terminate treatment for reasons of toxicity. To assess
the relationship between doxorubicin-induced toxicity and
outcome, we focused on hematologic parameters since these
are not largely impacted by factors other than the adminis-
trated chemotherapy and can be relatively easily captured.
Of the toxicities assessed, leucopenia and neutropenia grade
3/4 occurred most often, grade 3/4 thrombocytopenia was
very rare. Importantly, hematologic toxicity appeared not to
be cumulative after cycle 1 with occurrence of grade 3 tox-
icity remaining constant over the diverse cycles while grade
4 toxicity even tended to decrease after cycle 1. Altogether,
these data again emphasize the good tolerability of doxo-
rubicin in this group of advanced patients, which is of great
importance in the palliative setting.
Compared to toxicity, data on a dose-response relation-
ship for anti-tumor effects of doxorubicin are very scarce. In
pre-clinical models, in particular cell line models, there is in
general a clear dose-response relationship but to what extent
these data can be extrapolated to humans is unknown. One
paper suggests that doxorubicin should be given at doses
higher than 70mg/m2 [7] but the underlying evidence for
this is rather weak.
Nevertheless, in view of the assumed dose-response rela-
tions for both anti-tumor effects and hematologic toxicity,
one could anticipate an association between toxicity and
anti-tumor effects. This expectation is also commonly shared
by patients. In our experience, many patients can become
concerned when they do not experience toxicity during
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Figure 5. Subgroup of patients with time on treatment and PFS 63 days (N¼ 348) for each haematological toxicity grade during C1-3.
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treatment and ask ‘whether or not the chemotherapy actually
works, and whether the dose is high enough’. In this study,
however, we could not find an association between any of
the explored hematologic toxicities and outcome in terms of
RR, PFS and OS. This information is important as it may be
useful to reassure advanced STS patients that failure to
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Figure 6. Subgroup of patients with time on treatment and OS 63 days (N¼ 383) for each hematological toxicity grade during C1-3.
Table 2. Association of baseline characteristics and hematological toxicity experienced. (Odds ratio
estimates and corresponding 95% CI from a logistic multivariate regression).
Parameter Any AE grade 3–4 HGB: grade 3–4a WBC: grade 3–4 NEU: grade 3–4
Value at baseline 1.24 (0.93; 1.66) 11.4 (5.34; 24.2) 1.37 (0.59; 3.15) 1.17 (0.58; 2.34)
p¼ .143 p< .001 p¼ .464 p¼ .661
Age
<40 yrs 0.28 (0.15; 0.51) 0.13 (0.02; 0.71) 0.43 (0.24; 0.76) 0.30 (0.16; 0.54)
40–50 yrs 0.23 (0.13; 0.40) 0.59 (0.21; 1.69) 0.33 (0.20; 0.56) 0.24 (0.14; 0.41)
50–60 yrs 0.32 (0.19; 0.54) 0.60 (0.22; 1.61) 0.31 (0.19; 0.50) 0.33 (0.20; 0.55)
>¼60 yrs 1.00 1.00 1.00 1.00
p< .001 p¼ .132 p< .001 p< .001
BMI
<18.5 5.49 (1.42; 21.2) 2.36 (0.25; 22.5) 2.93 (0.96; 8.98) 7.60 (1.99; 29.0)
18.5–25 1.86 (1.19; 2.88) 0.94 (0.38; 2.30) 1.49 (0.95; 2.34) 2.31 (1.49; 3.58)
25–30 1.64 (1.03; 2.62) 0.72 (0.26; 2.01) 1.24 (0.77; 2.00) 2.00 (1.26; 3.18)
>¼30 1.00 1.00 1.00 1.00
p¼ .007 p¼ .763 p¼ .146 p< .001
PS
0 0.43 (0.14; 1.34) 1.50 (0.24; 9.25) 0.67 (0.25; 1.83) 0.66 (0.24; 1.83)
1 0.40 (0.13; 1.22) 1.19 (0.21; 6.80) 0.77 (0.28; 2.08) 0.59 (0.21; 1.64)
2þ 1.00 1.00 1.00 1.00
p¼ .268 p¼ .826 p¼ .624 p¼ .554
Gender
Female 1.91 (1.32; 2.76) 0.75 (0.34; 1.64) 1.51 (1.05; 2.19) 1.69 (1.18; 2.43)
Male 1.00 1.00 1.00 1.00
p< .001 p¼ .468 p¼ .028 p¼ .004
aVery few ’events’ so results are very unstable.
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experience haematological toxicity during treatment does
not equate to under-treatment and patients have not to be
worried if they do not experience some greater toxicity as it
does not reflect their response to therapy.
Apart from the fact that there is indeed no association at
all between hematologic toxicity and outcome, there are sev-
eral reasons to be considered why we could not identify
such a relationship. In patients with advanced STS, numerous
patients as well as tumor-related factors have been found to
determine outcome to doxorubicin, including WHO perform-
ance, gender and histologic subtype [11,12]. As a result, a
weak to modest association between hematologic toxicity
and outcome could therefore be obscured. In this study, sub-
analyses to establish whether there was a relationship
between doxorubicin-toxicity and outcome in specific histo-
pathological subgroups were not additionally performed
since it is unlikely that tumor characteristics such as histo-
logical subtype or tumor grading impact the toxicity to doxo-
rubicin. In addition, we would end up with relatively small
groups of patients hindering to establish robust conclusions.
Another reason underlying the lack of association
between toxicity and outcome might be that doxorubicin
levels reached in tumors, which are needed to exert anti-
tumor effects, could differ from the levels reached in bone
marrow causing myelosuppression. Many tumors are charac-
terised by leaky tumor vasculature, which results in a high
intra-tumoral interstitial pressure. This can hamper the pene-
tration of drugs from the peripheral circulation into tumors,
although this can differ per cytotoxic drug. For example, in
studies where simultaneously blood levels as well as intra-
tumoural levels were measured, 5FU levels in tumors
appeared to be substantially lower in tumors compared to
blood whereas for carboplatin, no difference could be
revealed [13,14]. To the best of our knowledge, such data
have not yet been generated yet for doxorubicin. Further
investigations to determine the relationship between both
blood drug levels and toxicity, and between blood drug lev-
els, intra-tumoural drug concentrations, and anti-tumor
effects are therefore necessary.
In addition to examining the relationship between toxicity
and outcome, we explored whether or not the baseline char-
acteristics (age, gender, BMI and performance score) were
associated with the occurrence of grade 3/4 hematological
toxicity. It revealed that female gender, higher age and a low
BMI were associated with an increased risk of grade 3/4
hematological toxicity, in particular grade 3/4 neutropenia.
Previous research on the impact of these baseline character-
istics on toxicity from doxorubicin-based chemotherapy is
rather scarce. In a recent meta-analysis on the effect of obes-
ity on outcome of adjuvant doxorubicin-based chemotherapy
in early breast cancer, it was found that in general obese
patients experienced less toxicity [15,16]. That the association
between body composition and doxorubicin’s pharmacokin-
etics is rather complex, is underlined by a study showing
that the systemic clearance of doxorubicin is reduced in
obese women, but not in obese men [5]. The effect sizes
seen in our study, particularly for the association between
age and neutropenia grade 3/4, are substantial taking into
account the often-delicate balance between anticipated
benefits versus untoward events when treating elderly
advanced STS patients and justify further research in
this area.
There are several limitations of this analysis. The retro-
spective nature of this study renders it prone to all the differ-
ent sources of bias inherent to retrospective analyses. In
addition, we focused on hematological toxicities only and
not on other toxicities. Another limitation is the fact that
patients included into clinical trials are often not reflective
for the populations seen in daily clinical practice. As a conse-
quence, the findings in our study may be generally applic-
able. Strong points of this study are the large number of
patients and the homogeneity in terms of treatment given
and patient’s and tumor characteristics since the eligibility
criteria of the clinical studies used in this analysis changed
little over the years.
In conclusion, in this large series of advanced STS patients
receiving doxorubicin monotherapy, treatment appeared to
be very well tolerated with almost no patients having to stop
treatment because of toxicity. This again confirms the toler-
ability of doxorubicin monotherapy in patients with
advanced STS, which is crucial, given the palliative setting of
this treatment. Furthermore, a relation between severity of
hematologic toxicity and outcome could not be demon-
strated, which is reassuring for patients who are concerned
they are being undertreated when toxicity fails to occur.
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